Meloxicam

Introduction Overview

Generic Name

meloxicam

Brand Name

Mobic

Dosage Form

Oral Tablets

Drug Class

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Pharmacokinetics

Absorption:
Meloxicam is well absorbed following oral administration, with peak plasma concentrations typically achieved within 5 to 6 hours post-dose. The drug exhibits high oral bioavailability, estimated to be approximately 89%, reflecting efficient gastrointestinal absorption. Food intake may slightly delay the time to peak concentration but does not significantly affect the extent of absorption. The absorption is consistent and predictable across patient populations, enabling once-daily dosing. Pharmacokinetic profiles show linearity across the therapeutic dosing range.

Distribution:
Meloxicam is extensively distributed throughout body tissues and fluids, exhibiting approximately 99% binding to plasma proteins, mainly albumin. This high protein binding capacity reduces the free active drug concentration but prolongs its half-life due to the drug reservoir effect. The volume of distribution is moderate, typically around 10 to 15 L, reflecting limited extravascular tissue penetration. Meloxicam crosses the placenta and is found in low concentrations in breast milk, which is clinically relevant for use during pregnancy and breastfeeding. Distribution to inflamed tissues appears adequate, supporting its efficacy in arthritis treatment.

Metabolism:
Meloxicam undergoes hepatic metabolism primarily via cytochrome P450 enzymes, chiefly CYP2C9, and to a lesser extent CYP3A4. It is extensively metabolized to inactive metabolites including 5'-carboxy meloxicam. The metabolic clearance is efficient, with no active metabolites contributing significantly to its pharmacologic effect. Genetic polymorphisms in CYP2C9 can alter meloxicam metabolism, resulting in interindividual variability in plasma levels and response. Co-administration with CYP2C9 inhibitors or inducers may affect meloxicam plasma concentration, necessitating dose adjustments or monitoring.

Elimination:
Meloxicam and its metabolites are eliminated primarily via the renal route (approximately 60%), with the remainder excreted in feces via biliary secretion. The elimination half-life is long, averaging 15 to 20 hours, enabling once-daily dosing. Renal impairment can reduce clearance, necessitating cautious use or dosage adjustment in patients with compromised kidney function. The drug is minimally removed by hemodialysis. The steady-state plasma concentration is typically achieved within 4 to 5 days of dosing, reflecting accumulation consistent with its elimination half-life.

Dosage Forms

Available Dosage Forms:
Mobic is available as oral tablets in strengths of 7.5 mg and 15 mg. These film-coated tablets are intended for once-daily oral administration.

Dosages for Adults and Adolescents:
- Osteoarthritis and Rheumatoid Arthritis: Initial dose typically 7.5 mg orally once daily. For patients requiring additional analgesia, maintenance dose may be increased to 15 mg once daily. Maximum recommended dose is 15 mg per day.
- Juvenile Rheumatoid Arthritis (Children 2 years and older): Dosage is weight-dependent, with children weighing 60 kg or greater receiving 7.5 mg once daily. Oral tablets are not approved for children weighing less than 60 kg.

Specific Patient Populations:
- Pediatric: Use of oral tablets in children weighing less than 60 kg is not recommended due to lack of demonstrated equivalent systemic exposure and efficacy.
- Elderly: Cautious dosing recommended due to increased risk of adverse effects and altered pharmacokinetics related to decreased renal function.
- Renal Impairment: Dose adjustment or close monitoring recommended; use with caution or avoid in severe renal impairment.
- Hepatic Impairment: Use caution; no specific dosage recommendations but consider the potential for altered metabolism.

Additional comments:
Oral tablet formulations have not demonstrated bioequivalence with oral liquid formulations and are not interchangeable. The lowest effective dose should be employed to reduce risk of adverse effects.

Mechanism Of Action

Meloxicam exerts its therapeutic effects primarily through inhibition of cyclooxygenase enzymes COX-1 and COX-2, with relative selectivity toward COX-2 at lower doses. Cyclooxygenases catalyze the conversion of arachidonic acid to prostaglandins and thromboxanes, which are mediators of pain, inflammation, and fever. By inhibiting COX-2 preferentially, meloxicam reduces the synthesis of pro-inflammatory prostaglandins, thereby alleviating symptoms associated with inflammatory conditions such as osteoarthritis and rheumatoid arthritis.

At the molecular level, meloxicam binds reversibly to the active site of COX enzymes, blocking access of arachidonic acid and thus diminishing downstream production of inflammatory mediators. This biochemical interaction leads to decreased sensitization of nociceptors and reduced inflammatory cell recruitment. Compared to non-selective NSAIDs, meloxicam's COX-2 preference limits gastrointestinal toxicity by sparing COX-1, which is responsible for protective gastric prostaglandin production, although at higher doses, COX-1 inhibition increases.

Meloxicam also modulates cellular pathways involved in inflammation by affecting leukocyte function and cytokine production, though these effects are less characterized. The drug reduces infiltration of inflammatory cells into joint tissues and decreases the release of pro-inflammatory cytokines, contributing to its efficacy in autoimmune arthritis.

Clinical studies have demonstrated that meloxicam's selective COX-2 inhibition translates into effective symptomatic relief with a comparatively improved gastrointestinal tolerability profile versus older, non-selective NSAIDs. However, the cardiovascular risk associated with COX-2 inhibition remains a consideration, with meloxicam displaying risks similar to other NSAIDs requiring cautious use in patients with cardiovascular disease or risk factors.

Pharmacological Actions

Selective inhibition of cyclooxygenase-2 (COX-2) enzyme reduces formation of pro-inflammatory prostaglandins.
Exhibits anti-inflammatory properties by decreasing inflammation and swelling in joint tissues.
Provides analgesic effects by reducing sensitivity of peripheral nociceptors to pain mediators.
Exerts antipyretic action through inhibition of prostaglandin synthesis in the central nervous system.
Demonstrates dose-dependent selectivity, with lower doses more COX-2 selective and higher doses inhibiting COX-1 as well.
Modulates leukocyte functions and decreases pro-inflammatory cytokine production.
Improves joint stiffness and tenderness associated with osteoarthritis and rheumatoid arthritis.
Demonstrates a prolonged duration of action enabling once-daily dosing.
Has a better gastrointestinal tolerability profile compared to traditional non-selective NSAIDs at recommended doses.
May influence platelet aggregation minimally due to limited COX-1 inhibition at therapeutic doses.

Therapeutic Or Clinical Uses

Management of osteoarthritis for relief of pain, stiffness, and inflammation.
Treatment of rheumatoid arthritis including symptom control of joint swelling and tenderness.
Relief of signs and symptoms of juvenile rheumatoid arthritis in children aged 2 years and older weighing 60 kg or more.
Used in chronic inflammatory joint conditions requiring long-term NSAID therapy.
Off-label use in inflammatory musculoskeletal disorders under clinician discretion.
Symptomatic treatment of acute musculoskeletal pain associated with inflammation.
Reduction of fever related to inflammatory conditions in the approved population.
Alternative NSAID therapy in patients who cannot tolerate other NSAIDs due to gastrointestinal side effects.
Adjunct treatment in autoimmune diseases to improve quality of life through symptom control.
Limited role in perioperative settings due to risk of bleeding and cardiovascular events.

Side Or Adverse Effects

Gastrointestinal discomfort including abdominal pain, nausea, vomiting, heartburn, constipation, diarrhea, and flatulence.
Increased risk of serious gastrointestinal bleeding, ulceration, and perforation, particularly in elderly patients.
Dizziness and headache reported in some patients during therapy.
Potential for allergic reactions including rash, urticaria, and severe skin reactions such as Stevens-Johnson syndrome.
Edema, fluid retention, and peripheral edema due to renal effects on sodium and water balance.
Elevations in liver enzymes and rare cases of hepatotoxicity presenting with jaundice and liver dysfunction.
Anemia or reduction in red blood cell count possibly due to gastrointestinal bleeding.
Renal impairment including acute renal failure, especially in patients with predisposing conditions.
Increased risk of cardiovascular thrombotic events including myocardial infarction and stroke, especially with long-term high-dose use.
Hypersensitivity reactions including asthma exacerbations in susceptible individuals.
Fatigue and malaise as reported in some post-marketing surveillance.
Potential hematologic effects such as thrombocytopenia or leukopenia.
Injection site reactions (for injectable formulations of meloxicam in other brands) are rare with oral tablets.
May cause delay in ovulation, impacting fertility in women of childbearing age.
Rare cases of central nervous system adverse effects such as aseptic meningitis.

Precautions

Use with caution in patients with a history of cardiovascular disease, hypertension, or risk factors for thrombotic events.
Avoid use immediately before or after coronary artery bypass graft (CABG) surgery due to increased risk of cardiovascular adverse events.
Monitor for signs of gastrointestinal bleeding, especially in elderly patients or those with a history of ulcers or bleeding disorders.
Perform renal function tests periodically during long-term therapy to detect possible renal impairment.
Avoid concurrent use with other NSAIDs or aspirin unless specifically directed by a healthcare provider.
Use caution in patients with hepatic impairment due to altered metabolism and clearance of meloxicam.
Consider potential drug interactions, particularly with anticoagulants, diuretics, lithium, methotrexate, and cyclosporine.
Avoid use during the last part of pregnancy (after 20 weeks gestation) due to risk of fetal harm, including renal impairment and premature closure of the ductus arteriosus.
Advise patients to avoid alcohol and smoking as these increase risk of gastrointestinal bleeding.
Use cautiously in patients with asthma or allergic-type reactions to aspirin or other NSAIDs.
Monitor blood pressure regularly due to potential for hypertension with long-term use.
Instruct patients on the importance of adhering to prescribed doses and not exceeding recommended duration of use.
Assess for signs of liver dysfunction during therapy, including jaundice or abnormal liver function tests.
Be alert for signs of severe skin reactions and discontinue drug immediately if symptoms appear.
Use cautiously in patients undergoing fertility treatment due to possible inhibition of ovulation.

Warnings

Increased risk of fatal cardiovascular thrombotic events including myocardial infarction and stroke, especially with prolonged or high-dose usage.
Not recommended for use just before or after coronary artery bypass graft (CABG) surgery.
Serious gastrointestinal adverse events including bleeding, ulceration, and perforation may occur at any time during therapy and can be fatal.
Older adults are at higher risk for gastrointestinal bleeding and perforation with NSAID therapy.
Severe allergic reactions including anaphylaxis, angioedema, and Stevens-Johnson syndrome have been reported.
Use in pregnancy during the last 20 weeks may result in fetal kidney problems and premature closure of the ductus arteriosus.
May cause kidney damage leading to renal failure, especially in patients with preexisting renal disease, dehydration, or heart failure.
Risk of liver toxicity including hepatitis and jaundice; monitor liver enzymes during long-term therapy.
Potential for fluid retention and worsening of hypertension or congestive heart failure.
Possible delay in ovulation leading to reduced fertility in female patients.
Patients should seek immediate medical attention for symptoms of cardiovascular events such as chest pain or neurological deficits.
Avoid concomitant use with other NSAIDs or anticoagulants without medical supervision due to additive risks.
Use caution when combined with antidepressants (SSRIs, SNRIs) due to increased risk of bleeding.
Use the lowest effective dose for the shortest duration necessary to minimize risks.
May mask fever and inflammation, potentially delaying diagnosis of infections.

Contraindication

Known hypersensitivity to meloxicam or any component of the formulation.
History of allergic reactions, including asthma, urticaria, or severe bronchospasm, triggered by aspirin or other NSAIDs.
Use in the setting of active or history of recurrent gastrointestinal bleeding or ulceration.
Severe hepatic impairment or active liver disease.
Severe renal impairment or patients on dialysis.
Use in the perioperative period of coronary artery bypass graft (CABG) surgery.
Patients with bleeding disorders or significant coagulopathies.
Third trimester of pregnancy due to risk of fetal toxicity.
Patients with asthma aggravated by NSAID use.
Concurrent use with other NSAIDs or aspirin (unless low-dose aspirin prescribed for cardioprotection and supervised by physician).
Known hypersensitivity to other components of the drug formulation.
History of Stevens-Johnson syndrome or toxic epidermal necrolysis associated with meloxicam or other NSAIDs.
Patients with severe heart failure where NSAID use is contraindicated.
Use in children under 2 years or those weighing less than 60 kg (oral tablets).

Drug Interactions

Concomitant use with anticoagulants (e.g., warfarin) increases risk of bleeding and requires monitoring.
Concurrent administration with lithium can increase lithium plasma levels, raising risk of toxicity.
Methotrexate clearance may be reduced, increasing potential for methotrexate toxicity.
Co-administration with cyclosporine may increase nephrotoxicity risk.
Caution with diuretics and antihypertensive agents as meloxicam can decrease their efficacy and induce fluid retention.
Combination with other NSAIDs or aspirin increases risk of gastrointestinal and cardiovascular adverse events.
Selective serotonin and norepinephrine reuptake inhibitors (SSRIs, SNRIs) may enhance bleeding risk when used with meloxicam.
Use with pemetrexed may increase risk of bone marrow and renal toxicity.
Sodium polystyrene sulfonate (Kayexalate) interaction details are limited but caution is advised.
Inhibitors or inducers of CYP2C9 (e.g., fluconazole, rifampin) can alter meloxicam plasma concentrations.
Alcohol consumption may exacerbate gastrointestinal adverse effects.
Use with corticosteroids may increase risk of gastrointestinal ulceration or bleeding.
Drugs that impair renal function may have additive nephrotoxic effects.
Use with antihypertensive drugs may reduce blood pressure control.
NSAIDs may diminish the cardioprotective effects of low-dose aspirin by inhibiting platelet function.

Preparations Of The Drug

Film-coated oral tablets available in 7.5 mg strength.
Film-coated oral tablets available in 15 mg strength.
Other brand preparations include injectable forms (Anjeso) not referenced in this data set.
Oral formulations are designed for once-daily dosing due to long half-life.
Generic meloxicam tablets approved by FDA as equivalents to Mobic.
Formulations may differ by manufacturer but generally consist of meloxicam with inert tablet excipients.
Tablets to be stored at room temperature away from moisture and heat.
Not approved for use in children weighing less than 60 kg for tablet formulations.
Extended-release formulations are not available for meloxicam; immediate-release tablets are standard.
No oral liquid formulation referenced for the Mobic brand.
Tablets intended for oral administration with or without food; taking with food may reduce gastrointestinal upset.
Other meloxicam products include capsules, chewable tablets, or injectables marketed under different brand names but not under Mobic designation.
Packaging typically includes child-resistant bottles with appropriate dosing instructions.
Manufacturers provide medication guides emphasizing cardiovascular and gastrointestinal risks.
Prescription only; no over-the-counter preparations under the Mobic name.